Trade

with

Genvec Inc
(NASDAQ: GNVC)
AdChoices
1.74
+0.03
+1.75%
After Hours :
-
-
-

Open

1.74

Previous Close

1.71

Volume (Avg)

14.12k (36.65k)

Day's Range

1.70-1.75

52Wk Range

1.19-4.25

Market Cap.

30.05M

Dividend Rate ( Yield )

-

Beta

2.08

Shares Outstanding

17.27M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 3.68M

    • Net Income

    • -10.02M

    • Market Cap.

    • 30.05M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -162.60

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.08

    • Forward P/E

    • -4.35

    • Price/Sales

    • 6.12

    • Price/Book Value

    • 2.33

    • Price/Cash flow

    • -4.09

      • EBITDA

      • -10.12M

      • Return on Capital %

      • -46.63

      • Return on Equity %

      • -61.47

      • Return on Assets %

      • -46.63

      • Book Value/Share

      • 0.75

      • Shares Outstanding

      • 17.27M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 9.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.40

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -82.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -24.61

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -162.60

            • 39.38

            • Net Profit Margin

            • -162.60

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -134.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.62

              • 2.92

              • Quick Ratio

              • 5.47

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.21

              • 2.21

              • Book Value/Share

              • 0.75

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.74

                • 217.39

                • P/E Ratio 5-Year High

                • -72.47

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.54

                • 124.82

                • Price/Sales Ratio

                • 6.09

                • 9.52

                • Price/Book Value

                • 2.32

                • 8.61

                • Price/Cash Flow Ratio

                • -4.09

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -61.47

                        (-88.50)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -46.63

                        (-62.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -61.47

                        (-87.40)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.29

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -10.29M
                      Operating Margin
                      -279.58
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.09
                      Ownership

                      Institutional Ownership

                      33.34%

                      Top 10 Institutions

                      35.64%

                      Mutual Fund Ownership

                      1.05%

                      Float

                      84.97%

                      5% / Insider Ownership

                      6.76%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Extended Market Index Fund

                      •  

                        88,782

                      • 0.00

                      • 0.51

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        39,959

                      • 0.00

                      • 0.23

                      • Vanguard US Equity Index

                      •  

                        14,500

                      • 49.48

                      • 0.08

                      • Master Extended Market Index Series

                      •  

                        8,267

                      • 0.00

                      • 0.05

                      • USAA Extended Market Index Fund

                      •  

                        8,264

                      • 34.42

                      • 0.05

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        8,140

                      • 0.00

                      • 0.05

                      • The Vanguard - Total Stk Mkt Idx Trust. CF

                      •  

                        7,932

                      • 0.00

                      • 0.05

                      • AXA/Lord Abbett Micro Cap Portfolio

                      •  

                        3,199

                      • 0.00

                      • 0.02

                      • Fidelity® NASDAQ Composite Index® Fund

                      •  

                        764

                      • 0.00

                      • 0.00

                      • Fidelity® Nasdaq Composite Tr Stk Fund

                      •  

                        601

                      • 9.47

                      • 0.00

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • EcoR1 Capital, LLC

                      •  

                        1,840,000

                      • 0.00%

                      • 13.45

                      • Cormorant Asset Management, LLC

                      •  

                        1,329,300

                      • 0.00%

                      • 7.70

                      • Perceptive Advisors LLC

                      •  

                        820,000

                      • 0.00%

                      • 4.75

                      • BlackRock Fund Advisors

                      •  

                        775,559

                      • +5.19%

                      • 4.49

                      • Sphera Funds Management Ltd.

                      •  

                        575,000

                      • 0.00%

                      • 3.33

                      • Vanguard Group, Inc.

                      •  

                        111,214

                      • +14.99%

                      • 0.64

                      • Dafna Capital Management LLC

                      •  

                        100,000

                      • 0.00%

                      • 0.58

                      • Geode Capital Management, LLC

                      •  

                        49,412

                      • -0.05%

                      • 0.28

                      • Morgan Stanley & Co Inc

                      •  

                        47,756

                      • -48.66%

                      • 0.28

                      • Northern Trust Investments, N.A.

                      •  

                        24,828

                      • -0.18%

                      • 0.14

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its devel...moreopment programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventati...moreve vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.lessless

                      Key People

                      Douglas J. Swirsky

                      Director/President/CEO/CFO/Chief Accounting Officer/Secretary/Treasurer

                      Dr. Wayne T. Hockmeyer,PhD

                      Chairman of the Board/Director

                      Marc R. Schneebaum

                      Director

                      Dr. William N. Kelley,M.D.

                      Director

                      Dr. Zola P. Horovitz,PhD

                      Director

                      • Genvec Inc

                      • 910 Clopper Road

                      • Gaithersburg, MD 20878

                      • USA.Map

                      • Phone: +1 240 632-0740

                      • Fax: +1 240 632-0735

                      • genvec.com

                      Incorporated

                      1992

                      Employees

                      11

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: